Novavax gets MHRA expanded conditional marketing authorisation for Nuvaxovid
The vaccine has been authorised for use in adolescents aged 12 to 17 years. The protein-based vaccine, Nuvaxovid is engineered from the genetic sequence of the initial SARS-CoV-2